Learning Center
New In Coagulation
Thursday, July 10, 2008
Investigational Oral Anticoagulant Bests Enoxaparin After Orthopedic Surgery
By Crystal Phend, Staff Writer, MedPage Today
Published: June 25, 2008
http://www.medpagetoday.com/Cardiology/VenousThrombosis/tb/9941
GOTHENBURG, Sweden, June 25 -- The investigational oral anticoagulant rivaroxaban (Xarelto), a selective factor Xa inhibitor, prevents venous thromboembolism after hip or knee arthroplasty better than enoxaparin (Lovenox), without a tradeoff in safety, according to two large international trials.
Rivaroxaban reduced the combined rate of deep-vein thrombosis, pulmonary embolism, and all-cause mortality at 36 days after total hip arthroplasty compared with the nonselective factor Xa inhibitor enoxaparin (1.1% versus 3.7%, P<0.001), style="font-weight: bold;">Primary source:
New England Journal of Medicine
Source reference:
Eriksson BI, et al "Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty" N Engl J Med 2008; 358: 2765-75.
Additional source:
New England Journal of Medicine
Source reference:
Lassen MR, et al "Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty" N Engl J Med 2008; 358: 2776-86.
Donna Castellone
|
